Fundraising Fox
/Companies
Sign in

Veratx

NASDAQ: VERA

South San Francisco, US · Founded 2016 · 359 employees on LinkedIn · 5 known investors

Find your way into Veratx

691 people in our graph share verified history with the Veratx team — schools, employers, funds. One of them is your warm intro.

Geoffrey Smithunlockedknows Marshall Fordyce · together at The Rockefeller University (overlapped)
×11knows the team · via Kleiner Perkins

Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

BiotechDigital HealthMedical Devices

Founders & leadership

Veratx was founded in 2016 by Marshall Fordyce.

MF
Marshall FordyceFounder and Chief Executive OfficerMarshall Fordyce is the founder and CEO of Vera Therapeutics, a biopharmaceutical company developing therapies for immunological and rare diseases. He previously held roles at Gilead Sciences, where he contributed to multiple FDA drug approvals in HIV and hepatitis treatment.

Board

BSBeth Seidenberg
Beth SeidenbergBoard directorFounding Managing Director at Westlake Village BioPartners
MKMaha Katabi
Maha KatabiBoard directorGeneral Partner at Sofinnova Ventures
KVKurt von Emster
Kurt von EmsterBoard directorManaging Partner at Abingworth
PEPatrick Enright
Patrick EnrightMember Board of DirectorsManaging Director at Longitude Capital
AC
Andrew ChengBoard director
SM
Scott MorrisonBoard director

Investors · 5

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: the S-1 prospectus · the VCSheet dataset · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us

AbingworthreportedLondon · $15M – $30Mvia Kurt von Emster · board

How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us

Sofinnova Venture PartnersreportedMenlo Park

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$70.7M disclosed across 1 round · 2020

▶$70.7MraisedFeb 2021 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Marshall FordyceExecutive Officer, Director
  • Andrew ChengDirector
  • Scott MorrisonDirector
  • Beth SeidenbergDirector
  • Maha KatabiDirector
  • Kurt von EmsterDirector
  • Patrick EnrightDirector
Offering amount
$70.7M
Amount sold
$70.7M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$389.4Mvaluation at IPOFeb 2022 · $15.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Veratx do?
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Who founded Veratx?
Veratx was founded by Marshall Fordyce in 2016.
Who are Veratx's investors?
Veratx's investors include Kleiner Perkins, Longitude Capital, Sofinnova Ventures, Abingworth, Sofinnova Venture Partners.
How much funding has Veratx raised?
Veratx has disclosed $70.7M raised across 1 round.
Where is Veratx headquartered?
Veratx is headquartered in South San Francisco, US.